替格瑞洛辅助治疗冠心病心绞痛的临床效果及安全性

Clinical efficacy and safety of ticagrelor in the adjuvant treatment of coronary heart disease and angina pectoris

目的分析替格瑞洛辅助治疗冠心病心绞痛的临床效果及安全性。方法将2018年7月至2020年7月收治的120例冠心病心绞痛患者依据治疗方法分为对照组(n=60,瑞舒伐他汀治疗)和研究组(n=60,瑞舒伐他汀与替格瑞洛联合治疗)。比较两组患者的治疗效果。结果治疗后,两组的CRP、IL-6、MPO水平均降低,且研究组低于对照组(P<0.05)。治疗后,研究组的心率低于对照组,LVEF高于对照组(P<0.05)。研究组的不良反应总发生率低于对照组,治疗总有效率高于对照组(P<0.05)。结论替格瑞洛辅助治疗冠心病心绞痛的效果显著,能够改善患者的心功能,减轻炎症反应。

Objective To analyze the clinical efficacy and safety of ticagrelor in the adjuvant treatment of coronary heart disease and angina pectoris.Methods A total of 120 patients with coronary heart disease and angina pectoris admitted from July 2018 to July 2020 were divided into control group(n=60,rosuvastatin treatment)and study group(n=60,rosuvastatin combined with ticagrelor treatment)according to treatment methods.The therapeutic effect of the two groups was compared.Results After treatment,the levels of CRP,IL-6 and MPO in both groups decreased,and those in the study group were lower than the control group(P<0.05).After treatment,the heart rate of the study group was lower than that of the control group,and LVEF was higher than that of the control group(P<0.05).The total incidence of adverse reactions in the study group was lower than that in the control group,and the total effective rate of treatment was higher than that of the control group(P<0.05).Conclusion Ticagrelor in the adjuvant treatment of coronary heart disease and angina pectoris has a significant effect,and it can improve the heart function and decrease the inflammatory reaction.